Home › Funds › Novo Holdings A/S › AVLN
Novo Holdings A/S position in AVLN
AVALYN PHARMACEUTICALS INC · Health Care
Novo Holdings A/S reported holding 3,449,191 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$98.3M, representing 6.60% of its reported portfolio and ranking #5 among its reported holdings. Novo Holdings A/S has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Novo Holdings A/S's AVLN position evolved
Novo Holdings A/S first disclosed a stake in AVLN in Q2 2026 at 3,883,289 shares (US$127.8M). Across 2 filings, Novo Holdings A/S increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,449,191 shares valued at US$98.3M — a reduction of -434,098 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 3.88M | $127.84M | New |
| Q3 2026 | 3.45M | $98.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVLN and 13F data
AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 114 other funds we track also report a position in AVLN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.3M), PERCEPTIVE ADVISORS LLC (US$76.2M), MONTANOVA CAPITAL, LLC (US$71.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVLN
- SR ONE CAPITAL MANAGEMENT, LP 3.31M sh · $94.26M · Q3 2026
- PERCEPTIVE ADVISORS LLC 2.68M sh · $76.22M · Q3 2026
- MONTANOVA CAPITAL, LLC 2.50M sh · $71.31M · Q3 2026
- NVP Associates, LLC 2.27M sh · $64.63M · Q3 2026
- Catalio Capital Management, LP 1.70M sh · $48.40M · Q3 2026
- Bellevue Group AG 1.35M sh · $38.46M · Q3 2026
- Soleus Capital Management, L.P. 1.02M sh · $29.03M · Q3 2026
- Andera Partners 929.82K sh · $26.49M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 866.79K sh · $24.69M · Q3 2026
- TPG GP A, LLC 773.07K sh · $22.02M · Q3 2026
- BRAIDWELL LP 744.46K sh · $21.21M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 731.00K sh · $20.83M · Q3 2026
More on Novo Holdings A/S
FAQ
How long has Novo Holdings A/S held AVLN?
Novo Holdings A/S has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Novo Holdings A/S's current position in AVLN?
As of Q3 2026, Novo Holdings A/S holds 3.45M shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $98.27M, representing 6.60% of its reported portfolio and ranking #5.
Has Novo Holdings A/S been buying or selling AVLN?
In the latest 13F filing (Q3 2026), Novo Holdings A/S reduced its position in AVLN.
Which other funds hold AVLN?
Other major institutional holders of AVLN include SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, MONTANOVA CAPITAL, LLC, among 114 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.